As Sangamo Biosciences (SGMO) Market Valuation Rose, Ecor1 Capital Lowered by $35.19 Million Its Holding; Teekay Tankers LTD Cl Af (TNK) Shareholder Berson & Corrado Investment Advisors Raised Holding

February 24, 2018 - By mmahotstuff

Berson & Corrado Investment Advisors Llc increased its stake in Teekay Tankers Ltd Cl Af (TNK) by 84.49% based on its latest 2017Q3 regulatory filing with the SEC. Berson & Corrado Investment Advisors Llc bought 360,875 shares as the company’s stock declined 21.54% while stock markets rallied. The institutional investor held 787,988 shares of the marine transportation company at the end of 2017Q3, valued at $1.28M, up from 427,113 at the end of the previous reported quarter. Berson & Corrado Investment Advisors Llc who had been investing in Teekay Tankers Ltd Cl Af for a number of months, seems to be bullish on the $337.94M market cap company. The stock increased 2.44% or $0.03 during the last trading session, reaching $1.26. About 1.48 million shares traded. Teekay Tankers Ltd. (NYSE:TNK) has declined 45.94% since February 24, 2017 and is downtrending. It has underperformed by 62.64% the S&P500.

Ecor1 Capital Llc decreased its stake in Sangamo Biosciences Inc (SGMO) by 91.34% based on its latest 2017Q3 regulatory filing with the SEC. Ecor1 Capital Llc sold 2.35 million shares as the company’s stock rose 95.00% with the market. The institutional investor held 222,388 shares of the health care company at the end of 2017Q3, valued at $3.34 million, down from 2.57 million at the end of the previous reported quarter. Ecor1 Capital Llc who had been investing in Sangamo Biosciences Inc for a number of months, seems to be less bullish one the $2.11B market cap company. The stock decreased 1.77% or $0.45 during the last trading session, reaching $24.95. About 3.83 million shares traded or 112.09% up from the average. Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has risen 29.78% since February 24, 2017 and is uptrending. It has outperformed by 13.08% the S&P500.

Investors sentiment decreased to 1.57 in 2017 Q3. Its down 0.02, from 1.59 in 2017Q2. It fall, as 17 investors sold SGMO shares while 32 reduced holdings. 27 funds opened positions while 50 raised stakes. 51.93 million shares or 2.16% more from 50.83 million shares in 2017Q2 were reported. Ra Capital Ltd Co reported 1.25 million shares or 1.69% of all its holdings. Voya Investment Management Ltd Liability Corp, a Georgia-based fund reported 38,027 shares. Ubs Asset Mgmt Americas, Illinois-based fund reported 21,498 shares. Iguana Health Mngmt Limited Liability Com has invested 1.67% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Nationwide Fund Advisors reported 44,892 shares. Millennium Mngmt Limited Liability holds 0.02% or 942,097 shares in its portfolio. Meeder Asset Management Inc has 0% invested in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Fic Inc holds 5.2% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) for 909,437 shares. Employees Retirement Of Ohio has 121,388 shares. Janney Montgomery Scott Limited Company owns 11,528 shares. Proshare Advisors invested in 52,791 shares. Alliancebernstein Lp has invested 0% of its portfolio in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Frontier Mgmt Com Ltd Liability Com reported 0.05% in Sangamo Therapeutics, Inc. (NASDAQ:SGMO). Cormorant Asset Lc reported 400,000 shares. Ameritas accumulated 5,756 shares.

Since September 1, 2017, it had 0 buys, and 8 sales for $1.88 million activity. On Thursday, February 1 the insider Herberts Curt A. III sold $308,855. Mento Steven J also sold $237,159 worth of Sangamo Therapeutics, Inc. (NASDAQ:SGMO) shares. Conner Edward R. had sold 5,000 shares worth $92,436 on Tuesday, February 6.

Ecor1 Capital Llc, which manages about $750.32M US Long portfolio, upped its stake in Regulus Therapeutics Inc (NASDAQ:RGLS) by 1.53M shares to 5.24M shares, valued at $6.55 million in 2017Q3, according to the filing. It also increased its holding in Seattle Genetics Inc (NASDAQ:SGEN) by 15,000 shares in the quarter, for a total of 30,000 shares, and has risen its stake in Clovis Oncology Inc (NASDAQ:CLVS).

Analysts await Sangamo Therapeutics, Inc. (NASDAQ:SGMO) to report earnings on February, 27. They expect $-0.18 earnings per share, down 28.57% or $0.04 from last year’s $-0.14 per share. After $-0.15 actual earnings per share reported by Sangamo Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 20.00% negative EPS growth.

Among 10 analysts covering Sangamo Biosciences (NASDAQ:SGMO), 7 have Buy rating, 1 Sell and 2 Hold. Therefore 70% are positive. Sangamo Biosciences had 23 analyst reports since August 8, 2015 according to SRatingsIntel. Wedbush maintained the shares of SGMO in report on Wednesday, September 2 with “Buy” rating. The firm has “Neutral” rating given on Tuesday, November 1 by Wedbush. Wells Fargo maintained the stock with “Buy” rating in Thursday, February 22 report. The company was maintained on Wednesday, November 15 by Wedbush. Jefferies maintained Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Wednesday, September 2 with “Buy” rating. The firm has “Neutral” rating given on Thursday, August 4 by Janney Capital. Jefferies reinitiated Sangamo Therapeutics, Inc. (NASDAQ:SGMO) rating on Thursday, June 22. Jefferies has “Buy” rating and $1700 target. The company was downgraded on Wednesday, October 19 by Piper Jaffray. Zacks downgraded Sangamo Therapeutics, Inc. (NASDAQ:SGMO) on Tuesday, September 8 to “Sell” rating. The firm has “Buy” rating by Jefferies given on Friday, October 13.

Among 10 analysts covering Teekay Tankers (NYSE:TNK), 4 have Buy rating, 1 Sell and 5 Hold. Therefore 40% are positive. Teekay Tankers had 17 analyst reports since September 4, 2015 according to SRatingsIntel. The stock of Teekay Tankers Ltd. (NYSE:TNK) earned “Buy” rating by UBS on Thursday, October 22. The rating was upgraded by Deutsche Bank on Friday, November 6 to “Buy”. Credit Agricole initiated the shares of TNK in report on Tuesday, December 8 with “Outperform” rating. On Friday, May 20 the stock rating was downgraded by Bank of America to “Underperform”. The stock of Teekay Tankers Ltd. (NYSE:TNK) earned “Buy” rating by Seaport Global on Wednesday, May 4. The stock of Teekay Tankers Ltd. (NYSE:TNK) earned “Overweight” rating by Barclays Capital on Monday, January 11. The stock of Teekay Tankers Ltd. (NYSE:TNK) has “Hold” rating given on Tuesday, September 22 by Zacks. Danske Bank initiated it with “Hold” rating and $4.50 target in Wednesday, March 2 report. JP Morgan downgraded Teekay Tankers Ltd. (NYSE:TNK) on Tuesday, January 12 to “Underweight” rating. UBS downgraded Teekay Tankers Ltd. (NYSE:TNK) rating on Tuesday, July 26. UBS has “Neutral” rating and $3 target.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>